Hyperhomocysteinemia and C677T MTHFR Genotype in Patients With Retinal Vein Thrombosis

Abstract

Introduction: Elevated homocysteine (Hcy) is associated with the risk of deep vein thrombosis, pulmonary embolism, ischemic heart disease, and stroke. Several studies have suggested that hyperhomocysteinemia (HHcy) may predispose to retinal vein thrombosis (RVT) development. The aim of this study is to investigate the relationship between Hcy, C677T methylenetetrahydrofolate reductase (MTHFR) genotype, and RVT in patients compared with controls.

Materials and Methods: We evaluated the Hcy plasma level of 3114 consecutive participants in 2 Italian centers during a 2-year period. Hyperhomocysteinemia was found in 99 patients and 136 healthy participants. Of the 99 patients, 20 had RVT with a high prevalence of HHcy in the RVT subgroup (20.2%). This result suggested a possible relationship between HHcy and RVT development. We investigated 105 consecutive patients with recent diagnosis of RVT, and we compared them with 226 healthy controls to evaluate whether HHcy may be a risk factor for RVT.

Results: the prevalence of HHcy was higher in patients compared with controls (34.3% vs 14.2%; P < .001). The MTHFR C677T genotype was found in 69 of 105 (65.7%) patients with RVT (heterozygosity: 40 of 105 and homozygosity: 29 of 105). The control group showed the presence of MTHFR C677T genotype in 169 of 226 participants (74.8%; heterozygosity: 100 of 226 and homozygosity: 69 of 226) without difference between the 2 groups (P = .08).

Conclusion: our study suggests that HHcy is a possible risk factor for RVT development, while no association was found between RVT and the C677T MTHFR genotype.

Keywords

thrombophilia venous thromboembolism gene polymorphisms

References

Terrazzi P. , Di Micco P. , Quaglia I. , et al. Homocysteine, MTHFR C677T gene polymorphism, folic acid and vitamin B 12 in patient with retinal vein occlusion. Thromb J. 2005;3(Sep 7):13.

Klein R. , Klein B. , Moss SE , Meuer SM The epidemiology of retinal vein occlusion: the beaver dam eye study. Trans Am Ophthalmol Soc. 2000;98:133-141.

Haas S. Low molecular weight heparins in the prevention of venous thromboembolism in nonsurgical patients. Semin Thromb Hemost. 1999;25(suppl 3):101-105.

Wu-Wong JR Endothelial dysfunction and chronic kidney disease: treatment options. Curr Opin Investig Drugs. 2008;9(9): 970-982.

Gao W. , Wang YS , Zhang P. , Wang HY Hyperhomocysteinemia and low plasma folate as risk factors for central retinal vein occlusion: a case-control study in a Chinese population. Graefes Arch Clin Exp Ophthalmol. 2006;244(10):1246-1249.

Cahill M. , Karabatzaki M. , Meleady R. , et al. Raised plasma homocysteine as a risk factor for retinal vascular occlusive disease. Br J Ophthalmol. 2000;84(2):154-157.

Martin SC , Rauz S. , Marr JE , Martin N. , Jones AF , Dodson PM Plasma total homocysteine and retinal vascular disease. Eye . 2000;14(pt 4):590-593.

Vine AK Hyperhomocysteinemia: a risk factor for central retinal vein occlusion. Am J Ophthalmol. 2000;129(5):640-644.

Marcucci R. , Bertini L. , Giusti B. , et al. Thrombophilic risk factors in patients with central retinal vein occlusion. Thromb Haemostasis. 2001;86(3):772-776.

10.

Larsson J. , Hultberg B. , Hillarp A. Hyperhomocysteinemia and the MTHFR C677T mutation in central retinal vein occlusion. Acta Ophthalmol Scand. 2000;78(3):340-343.

11.

Boyd S. , Owens D. , Gin T. , et al. Plasma homocysteine, methylenetetrahydrofolate reductase C677T and factor II G20210A polymorphisms, factor VIII, and VWF in central retinal vein occlusion. Br J Ophthalmol. 2001;85(11):1313-1315.

12.

McGimpsey SJ , Woodside JV , Bamford L. , et al. Retinal vein occlusion, homocysteine and methylene tetrahydrofolate reductase genotype. Invest Ophthalmol Vis Sci. 2005;46(12): 4712-4716.

13.

Boushey CJ , Beresford SA , Omenn GS , Motulsky AG A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA. 1995;274(13):1049-1057.

14.

D’Angelo A. , Selhub J. Homocysteine and thrombotic disease. Blood. 1997;90(1):1-11.

15.

Ray JG Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med. 1998; 158(19):2101-2106.

16.

Wirta V. , Saransaari P. , Wirta O. , et al. Methylenetetrahydrofolate reductase gene polymorphism, hyperhomocysteinemia and occlusive retinal vascular disease in type 2 diabetic and non-diabetic subjects. Clin Nephrol. 2002;58(3):171-178.

17.

StataCorp. Stata Statistical Software: Release 10. College Station, TX: StataCorp LP; 2007.

18.

Biancardi AL , Gadelha T. , Borges WI , Vieira de Moraes H. Jr , Spector N. Thrombophilic mutations and risk of retinal vein occlusion. Arq Bras Oftalmol . 2007;70(6):971-974.

19.

Weger M. , Stanger O. , Deutschmann , et al. Hyperhomocyst(e)inemia and MTHFR C677T genotypes in patients with central retinal vein occlusion . Graefes Arch Clin Exp Ophthalmol. 2002;240(4):286-290.

20.

Abbate R. , Sardi I. , Pepe G. , et al. The high prevalence of thermolabile 5-10 methylenetetrahydrofolate reductase (MTHFR) in Italians is not associated to an increased risk for coronary artery disease (CAD). Thromb Haemost. 1998 ;79(4):727-730.

21.

Aucella F. , Margaglione M. , Grandone E. , et al. The C677T methylenetetrahydrofolate reductase gene mutation does not influence cardiovascular risk in the dialysis population: results of a multi-centre prospective study. Nephrol Dial Transplant . 2005;20(2): 382-386.

22.

Wilcken DE , Wilcken B. The natural history of vascular disease in homocystinuria and the effects of treatment. J Inherit Metab Dis. 1997;20(2):295-300.

23.

Peterson JC , Spence JD Vitamins and progression of atherosclerosis in hyper-homocysteinaemia. Lancet. 1998;351(9098): 263-263.